The MajesTEC-3 trial offers three critical takeaways for multiple myeloma management. First, teclistamab extended median progression-free survival by 7.3 months compared with standard care, providing meaningful additional disease control for patients in earlier treatment lines. Second, complete response rates were 2.6 times higher with teclistamab at 26.5% versus 10.2%, suggesting deeper, more durable disease responses. Third, while a manageable safety profile emerged, clinicians must monitor for common adverse events including infections (25.8%), neutropenia (23.2%), anemia (17.8%), and cytokine release syndrome (48.8%).
These findings support repositioning bispecific antibodies as viable earlier-line options, potentially altering treatment sequencing strategies and improving long-term patient outcomes. Appropriate patient selection and close safety surveillance remain essential for optimizing therapeutic benefit.
Read the full article on GMJ Newsroom.
Was this article helpful?
